drugset / Trial / NCT00233207
IC14 Antibodies to Treat Individuals With Acute Lung Injury
Phase 2
Terminated
13 enrolled
University of Washington
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedDouble-blindTreatment
Summary
This is a phase II, randomized, double-blind, placebo-controlled, safety and efficacy study of a recombinant chimeric monoclonal antibody against CD14 (IC14) in hospitalized patients with acute lung injury (ALI).
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC14 | Monoclonal antibody | — | — |